ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.
Location: United States, Michigan, Ann Arbor
Total raised: $158.8M
Investors 3
| Date | Name | Website |
| 17.03.2023 | Visionary ... | visionaryv... |
| - | Invest Mic... | investmich... |
| - | Grand Ange... | michiganca... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.09.2024 | Series D | $65M | - |
| 13.01.2022 | Series B | $46.9M | - |
| 24.12.2020 | Series B | $46.9M | - |
Mentions in press and media 17
| Date | Title | Description |
| 16.09.2024 | ONL Therapeutics Closes $65M Series D Financing | ONL Therapeutics, an Ann Arbor, MI-based clinical-stage biopharmaceutical company focused on advancing treatments of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), raised $65M in Series D funding. The ro... |
| 13.09.2024 | ONL Therapeutics Secures $65 Million to Revolutionize Vision Care | In the heart of Ann Arbor, a beacon of hope for vision preservation shines brighter. ONL Therapeutics, a clinical-stage biopharmaceutical company, has successfully closed a $65 million Series D financing round. This funding is not just a nu... |
| 13.09.2024 | ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing | Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN ARBOR, Mich., Sept. ... |
| 13.09.2024 | ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing | ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that it has secur... |
| 08.03.2023 | ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial | - |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9M Series B Financing | ONL Therapeutics, Inc.,, an Ann Arbor, Mich.-based clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on its second tranche of its Series B financing. The t... |
| 13.01.2022 | Eye disease biotech raises $46.9M in Series B; Journey Medical Corporation shells out $20M upfront for dermatology franchise | ONL Therapeutics — an Ann Arbor, MI biotech that got its initial backing from Novartis in a 2017 Series A for its lead candidate Fas inhibitor ONL1204 — just got its next cash infusion. The biotech announced this morning tha... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones | – Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – – Phase 1b studies in patients with OAG and... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones | – Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – – Phase 1b studies in patients with OAG and... |
| 26.12.2020 | ONL Therapeutics secures US$ 46.9M in Series B funding | - |
Show more